Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary<sup>®</sup>): Results of a Nationwide Dose Conversion Survey

<div>Recommended dosing and frequency strategy (<i>N</i> = 90).</div>

Parkinson’s Disease

fig2

Figure 2

Figure 2: Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary<sup>®</sup>): Results of a Nationwide Dose Conversion Survey 

Parkinson’s Disease

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey

Figure 2

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary^®): Results of a Nationwide Dose Conversion Survey